Marc Banjak
Net worth: 31 750 $ as of 2026-08-30
Net worth: 31 750 $ as of 2026-08-30
Mr. Marc A. Banjak is a Chief Legal Officer at iBio, Inc. Mr. Banjak was previously employed as a General Counsel by Dova Pharmaceuticals, Inc., a General Counsel by Istari Oncology, Inc., and a Member by The Colorado Bar Association.
He received his undergraduate degree from Franklin & Marshall College and a graduate degree from Sturm College of Law.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IBIO, INC. 0.07% | 2026-08-31 | 25,000 ( 0.07% ) | 31 750 $ | 2026-08-30 |
| Companies | Position | Start |
|---|---|---|
| IBIO, INC. | General Counsel | - |
| Companies | Position | End |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | General Counsel | 2021-03-31 |
The Colorado Bar Association | Corporate Officer/Principal | - |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology that focused on novel immuno-oncology and immunotherapy products | Comptroller/Controller/Auditor | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
Franklin & Marshall College
Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Colorado Bar Association | |
iBio, Inc.
iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins | Health Technology |
Sturm College of Law
Sturm College of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs with disorder of low blood platelet count | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology that focused on novel immuno-oncology and immunotherapy products | Health Technology |
Select your edition
All financial news and data tailored to specific country editions